Fluocinolone Acetonide

Press Release Paris, 3 rd March, 2026 Progress against FOCUS-27 in a deteriorating environment Accelerated transformation to strengthen the operating model Full-year 2025 results €848.2 million net sales (7.0) % decline year-on-year – (5.9) % on a comparable basis EBITDA at €9.9 million compared to €(43.6) million in 2024 Core EBITDA at €66.2 million compared to €50.4 million in 2024 7.8% Core EBITDA margin vs 5.5% in 2024 €10M decrease in OPEX 1 , driven by effective cost control measures € (130.6) million Operating Income compared to € (120.4) million in 2024 €(77.8) million impairments of assets € (211.2) million Net Income compared to € (130.6) million in 2024 € (77.0) million CAPEX – 55% dedicated to growth € 68.2 million Net Cash Position at the end of December 2025 2026 outlook 2 Due to the impact of portfolio rationalization, and considering the challenging business environment, the company expects a decrease of around 10% in net sales 3 in 2026. In this context, EUROAPI will accelerate its transformation to protect profitability and expects to maintain its FY 2026 Core EBITDA margin broadly in line with FY 2025. FOCUS-27 plan update Transformation remains on track in a challenging environment with group fundamentals reinforced through timely execution of the initial phase of the plan: APIs portfolio streamlined as scheduled Haverhill site successfully divested Cost base sustainably reduced through enhanced operational efficiencies. With 2026 and 2027 sales now expected to be below initial assumptions, incremental Core EBITDA target will not be achieved in 2027. Consequently, we are accelerating the plan and launching additional business initiatives to continue to strengthen the operating model. “0ur 2025 financial results reflect improved cost discipline, and we are prepared to navigate 2026 with the same rigor and focus,” said David Seignolle, Chief Executive Officer of EUROAPI . “The fast-moving business environment we face requires us to accelerate and intensify our efforts. We will take the necessary actions to drive profitable growth, with a long-term strategy anchored in discipline and value creation, in the interests of all stakeholders.” 2025 consolidated key figures (in € millions) FY-2025 FY-2024 Net Sales 848.2 911.9 Year-on-year change in % -7.0% -10.0% Gross profit 144.8 142.4 Gross Profit Margin 17.1% 15.6% EBITDA 9.9 (43.6) Core EBITDA 66.2 50.4 Core EBITDA Margin 7,8% 5.5% Net Income (211.2) (130.6) Basic EPS (in euros) (2.23) (1.38) Free Cash Flow before Financing 51.5 15.0 Net (Debt) / Cash Position 68.2 24.6 2025 non-financial key figures FY-2025 FY-2024 4 GHG emissions scope 1 and 2 5 (metric tons of CO 2 e) 83,962 96,466 Share of renewable energy consumption 33% 26% GHG emissions scope 3 (metric tons of CO 2 e) 482,015 535,398 Water withdrawal (in 000 m 3 ) 17,571 17,181 Waste produced (in metric tons) % recycled or recovered 52,297 55% 60,384 60% Solvent used (in metric tons) % Solvent Recycling 82,845 75% 70,564 74% Total recordable Injury Frequency (per 1,000,000 hours worked) 4.4 4.6 Women in Extended Leadership Team (% women in total workforce) 27.8% 28.5% 34.2% 28.8% 2025 Net Sales EUROAPI 2025 Net Sales reached €848.2 million, -7.0% versus 2024. On a comparable basis (at CER and excluding the Haverhill perimeter impact 6 ), net sales would have declined by 5.9%. Net sales per type of activity 7 (in € million) FY-2025 FY-2024 Change API Solutions – Other clients 420.1 354.1 18.6% API Solutions – Sanofi 203.8 309.5 -34.2% API Solutions 623.8 663.6 -6.0% CDMO – Other clients 117.2 135.6 -13.6% CDMO – Sanofi 107.2 112.7 -4.9% CDMO 224.4 248.3 -9.6% Net sales 848.2 911.9 -7.0% Total Net Sales – Sanofi 310.9 422.2 -26.4% Total Net Sales – Other clients 537.3 489.7 9.7% API Solutions API Solutions net sales decreased by 6.0% The decline in sales to Sanofi was mainly due to three factors: an unfavorable comparison base with the stock clearance of Buserelin in 2024 (€21 million), the decline of volume of Sevelamer in H1, and the divestment of Haverhill at the end of June 2025. Excluding Opella, API Solutions sales to Sanofi would have decreased by 25.7% year-on-year. Sales to Other Clients increased as a result of the cross-selling strategy (contributing to approximately 5.1% of API Solutions sales to Other Clients in 2025) and the addition of 31 new clients. Excluding Opella, API Solutions sales to Other Clients would have increased by 4.5% year-on-year. The discontinued APIs accounted for approximately €70 million in FY2025 sales, including around €20 million related to strategic stockpiling from customers. CDMO CDMO sales decreased by 9.6% CDMO activity included 39 active projects in 2025, compared to 58 in 2024. Middle and large companies now account for 66% of the CDMO pipeline versus 62% the previous year. As we continued to derisk our portfolio, Phase III and Commercial phase projects represented 70% of the portfolio versus 60% in 2024. Commercial Phase (CMO) projects represented 89% of total CDMO sales, amounting to €200.3 million, down 9.7% compared to previous year. Growing demand for Poly-L-Lactic Acid (PLLA) produced in Vertolaye and used in skin care products was more than offset by the downsizing and discontinuation of pre-carve out contracts. Phase I, II and III CDMO projects represented 11% of total CDMO sales for a total value of €24.1 million, down 9.1% versus last year. Net Sales per type of molecule (in € million) FY-2025 FY-2024 Change Large molecules 62.0 90.5 -31.5% Highly potent molecules 81.3 91.0 -10.7% Biochemistry molecules derived from fermentation 117.1 110.1 6.3% Complex chemical synthesis molecules 587.9 620.3 -5.2% Net Sales 848.2 911.9 -7.0% The decrease in Large molecules was driven by an unfavorable comparison base as 2024 included a €21 million one-off impact from Buserelin stock clearance. Despite growth in glaucoma and veterinary prostaglandin therapeutics areas, overall sales of Highly potent molecules declined due to the completion of two early stage CDMO contracts and the intensified market pressure from Asian competitors. Growth in Biochemistry molecules derived from fermentation was driven by stockpiling of discontinued products, and a favorable base due to the temporary closure of the Brindisi site in 2024. Sales of Vitamin B12 remained flat amid persisting competitive dynamics. Reduced sales in Complex chemical synthesis molecules were mainly due to the divestment of Haverhill site in June 2025. Financial performance (in € million) FY-2025 FY-2024 Net Sales 848.2 911.9 Other revenues 4.4 7.3 Gross profit 144.8 142.4 Gross Profit Margin 17.1% 15.6% EBITDA 9.9 (43.6) Non-recurring items 56.3 94.0 Core EBITDA 66.2 50.4 Core EBITDA Margin 7.8% 5.5% Operating Income (130.6) (120.4) Finance revenues/costs (7.5) (19.1) Income before tax (138.2) (139.6) Income tax (72.9) 9.0 Net income/(loss) (211.2) (130.6) EPS (in euros) (2.23) (1.38) Average number of shares outstanding (in millions) 94.7 94.5 Fully diluted EPS (in euros) (2.23) (1.38) Average number of shares after dilution (in millions) 94.9 94.6 Gross profit totaled €144.8 million, an increase from €142.4 million in 2024, with the Gross Profit margin up 150 basis points year-on-year to 17.1%. Core EBITDA amounted to €66.2 million, up 31.2% compared to €50.4 million in 2024. The core EBITDA margin was 7.8% compared to 5.5% in 2024. The increase in Core EBITDA margin was driven by the decrease in OPEX from lower personnel costs and substantial savings in external expenditures, supported by strengthened financial discipline and effective cost control measures. Key components of the change in Core EBITDA margin FY25/FY24 in percentage points (rounded figures) FY 2024 Core EBITDA margin 5.5% Impact of Buserelin’s stock clearance in 2024 -0.9 pt Volume -1.0 pt Price and Mix +1.3 pts Impact of Discontinued APIs +0.3 pt Industrial Efficiencies +1.2 pts Energy and Raw Materials +0.9 pt Other Gross Margin Impacts +0.3 pt OPEX +1.0pt Brindisi site -1.4 pt Haverhill site +0.6 pt FY 2025 Core EBITDA margin 7.8% EBITDA was €9.9 million compared to €( 43.6) million in 2024, including €58.8 million of exceptional items linked to FOCUS-27 plan 8 , of which €36.1 million of idle costs 9 linked to the execution of FOCUS-27 €6.6 million in internal and external costs related to the company’s transformation €13.7 million of employee-related expenses linked to the FOCUS-27 plan. Operating Income was €(130.6) million compared to €(120.4) million in 2024. The €77.8 million impairment of assets was triggered by the discontinuation of Vitamin B12 project in Elbeuf due to lower-than-expected economic potential in an increasingly price competitive environment, combined with a revision of growth assumptions to align with the latest market dynamics. Financial income was €(7.5) million, compared with €(19.1) million in 2024, which included the impact of the refinancing of the Revolving Credit Facility. Income before tax was €(138.2) million. The €(72.9) million income tax expense in 2025 primarily derives from impairment of deferred tax assets following the update of growth assumptions. Net income was €(211.2) million in 2025. Net Debt Position and Cash Flow (in € million – rounded figures) 31 December 2025 Net Cash/(Debt) position – December 2024 24.6 10 Cash Flow from Operating activities 128.5 Of which change in Working Capital 120.1 (Increase)/decrease in inventories 38.9 (Increase)/decrease in trade receivables 45.4 Increase/(decrease) in trade payables 1.6 Other current assets and liabilities 34.3 Cash Flow from Investing Activities (CAPEX) (77.0) Cash Flow from Financing activities -8.4 Of which Cost of Debt (3.0) Exchange rate 0.5 Net Cash/(Debt) position – December 2025 68.2 The company ended 2025 with a €68.2 million Net Cash position , compared to €24.6 million Net Cash at the end of December 2024 . The improvement was driven by Working Capital , including further reduction of inventories. Months on Hand at the end of December 2025 was 7.0 compared to 6.9 at the end of 2024. The decrease in receivables was notably driven by the factoring program in March 2025 (€26.5 million were factored by end 2025). DSO was 36 compared to 39 in December 2024 driven by enhanced cash collection. Other current assets and liabilities include a €36 million paid by Sanofi to reserve a minimum available capacity for five selected products as part of the financing of FOCUS-27, €21 million up-front grant from the IPCEI program, and €6.5 million related to the monetization of 2022, 2023, and 2024 Research Tax Credit in France. Capex reached €(77.0) million (9.1% of Net Sales), of which 55% was dedicated to growth projects. Free Cash Flow before financing activities reached €51.5 million , compared to €15.0 million at the end of 2024. 11 (in € million) 31 December 2025 31 December 2024 Bank Cash Balances 113.8 75.2 Bank Overdraft, derivatives and accrued interests (0.6) (0.7) Revolving Credit Facilities (45.0) (50.0) Net Debt Position 68.2 24.6 FOCUS-27 UPDATE The execution of the FOCUS-27 plan over 2024 and 2025 has reinforced EUROAPI’s operating base. Since its launch in 2024, the most critical actions planned for this initial phase have been delivered. Portfolio streamlining The APIs portfolio has been streamlined toward higher added value products. In 2025, 66% of APIs catalog sales were generated by differentiated products. In parallel, the CDMO roadmap has been refocused towards de-risked, late-stage projects and 70% of year-end 2025 CDMO projects were in late stage. Footprint rationalization and high-return CAPEX In line with FOCUS-27, the Haverhill site in the UK was sold to Particle Dynamics on 30 June 2025 12 . The mothballing of one workshop at the Frankfurt site has been completed, and consolidation of the remaining three workshops into one is ongoing. 54% of the €185 million CAPEX invested over the past two years was dedicated to growth and performance Cost reductions and organizational transformation The cost savings initiatives implemented since the launch of the plan have reduced the company’s cost base, delivering close to €20 million OPEX savings 13 . These savings were primarily achieved through new procurement, commercial and IT operating models, a more agile R&D organization, and tight control of General Expenses. Industrial efficiency programs have structurally improved productivity across all manufacturing sites. Headcount has been reduced across all functions. Approximately 380 positions 14 have been removed out of the 550 initially targeted, ahead of schedule. In parallel with the deployment of FOCUS-27, EUROAPI and the French Government signed in July 2025 an agreement granting of up to €140 million in public aid to support part of R&D costs and investments related to the IPCEI Med4Cure project. However, a fast-evolving business environment combined with certain internal challenges put pressure on the pace of delivery, calling for accelerated execution, and additional business initiatives. Asian competition continues to intensify, increasing pricing pressure in mature APIs, reinforcing the need for European players to move further toward higher-barrier segments. While APIs’ customers are placing greater emphasis on resilient and reliable supply chains, the pharmaceutical industry has started to outsource more late-stage complex commercial projects, favoring integrated CMO and CDMO partners. Historically framed as a key driver for future growth, the early-stage CDMO roadmap is progressing at a slower pace than anticipated. In parallel, the Commercial-phase CMO business requires increased focus to improve capacity utilization and accelerate volume ramp-up. Despite the improvement in the overall manufacturing processes, the project aimed at increasing Vitamin B12 capacities and enhancing cost efficiency has been stopped due to a deteriorating competitive environment, including rising pressure from Asian low-cost imports. To address these dynamics, EUROAPI is accelerating the execution of the key pillars of the plan and launching additional initiatives to strengthen the company’s operating model. Accelerated execution Further acceleration in high-margin complex molecules, achieved through a more active management of the API portfolio, with a focus on Prostaglandins, Corticosteroids, Opiates, and selected complex small molecules. Commoditized products will be deprioritized if necessary. Enhanced Commercial CMO offer, grounded in a strengthened commercial strategy and supported by sovereign and reshoring tailwinds. This will secure volumes and drive higher capacity utilization. Operational Excellence Model driving standardized, and digitalized manufacturing processes. Deeper organizational transformation, aligning skills and capabilities with a fast-evolving environment. Launch of additional initiatives Geographic expansion - The customer base will be widened to under leveraged territories, for example North America and Latin America. Refocused CDMO - The CDMO businesses will concentrate on strategic customers and complex molecules, notably high value Peptides and Oligonucleotides. Supply chain optimization - To further improve the competitiveness of its industrial model, the company will optimize its supply chain to reduce costs while securing end-to-end control. With 2026 and 2027 sales now expected to be below initial assumptions, the €75 - 80 million incremental Core EBITDA target will not be achieved in 2027. Restructuring costs are expected to remain in the €110 - €120 million range. The €350 to 400 million CAPEX envelope planned for 2024 and 2027 is maintained. With a clear customer value-proposition, and a more cost-efficient operating model, EUROAPI aims to position itself as a reliable European sovereign supplier for complex APIs and a trusted partner for new drug development. Environment – Social - Governance Commitments Initiatives 2025 score Accelerate innovation for environmental sustainability 100% sites ISO14001 and 50001 certification by 2025 100% ~ 100% sites with purchased electricity from renewable sources by 2025 100% -42% of CO2 emissions reduction (vs. 2022) by 2030 (scope 1&2) – Objective revised in 2024 -24% vs. 2022 -25% GHG emissions reduction (vs. 2022) by 2030 (scope 3) -33% vs. 2022 -20% water withdrawal (vs. 2020) by 2030 -16% vs. 2020 Create a safe workplace LTI – Lost Time Injury frequency rate to 1.5 by 2025 3.1 TRI – Total Recordable Injury frequency rate to 2.5 by 2025 4.4 Uphold best-in-class corporate governance 100% completion of code of ethics and alert management by 2025 94% In 2025, EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi), confirming the company’s alignment with the Paris Agreement trajectory. 2025 emissions data confirm good progress against these targets, with half of the targeted reduction for 2030 already achieved on scope 1+2, and scope 3 reduction already exceeded. Despite our continuous efforts to limit accidents, the rate of injuries remained stable in 2025, and above our 2025 LTI target of 1.5 and TRI target of 2.5. Majority of these accidents could be qualified as minor (with a significant number being slip -trip-fall) but still resulted in conditions where the employee was unable to return immediately to physical activity. The accident prevention plan launched in 2025 will be further rolled out in 2026 and reinforced with enhanced root cause analysis. Turn-over and re-organization led to coming short of our target of 30% women in ELT by the end of 2025, although 2023 and 2024 ratio showed an increase and exceeded our target. FY 2026 Guidance operational and financial main drivers EUROAPI full-year guidance was built on the following assumptions: Net Sales are expected to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 2026 15 ), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts. The Core EBITDA margin is expected broadly with 2025 level. Industrial efficiencies and additional OPEX savings expected should be offset by unfavorable fixed cost absorption due to lower volume. EBITDA should be impacted by restructuring costs. CAPEX to sales ratio is expected around 8% of sales. Glossary and definition of non-GAAP indicators Net Sales at Constant Exchange Rate (CER) FY 2025 sales at FY 2024 Exchange rates On a comparable basis At constant perimeter and constant exchange rates EBITDA and Core EBITDA EBITDA corresponds to operating income (loss) restated for depreciation and amortization and net impairment of intangible assets and property, plant and equipment. Core EBITDA thus corresponds to EBITDA restated for restructuring costs and similar items (excluding depreciation and write-downs), allocations net of reversals of unutilized provisions for environmental risks, and other items not representative of the Group’s current operating performance or related to the effects of acquisitions or disposals. Cash Flow before Financing activities Cash Flow before Financing activities corresponds to the sum of Cash Flow from Operating Activities and Cash Flow from Investing Activities as presented in the consolidated statement of Cash Flow. Months on Hand (MOH) Net Inventory value at the of the period divided by Net Sales New clients Clients representing at least €50,000 net sales on the year. Cross Selling Selling a different product to an existing client that is already buying one or several products from EUROAPI. Early-stage and Late-stage projects Early-stage: pre-clinical, phase 1, and phase 2 Late-stage: phase3, in validation, and commercial Presentation of 2025 results EUROAPI’s management will hold an audio webcast presentation (04 March 2026) at 8 :30 a.m. CET. (live and replay), and the presentations are available on the corporate website Full-Year 2025 Results EUROAPI consolidated financial statements as of December 31, 2025, were approved by the Board of Directors on March 3 rd , 2026. A presentation related to this announcement is also available on EUROAPI’s website ( ). Audit procedures on the consolidated financial statements are being finalized, and the certification report on the consolidated financial statements will be issued once the management report has been approved by the Board of Directors and verified by the Statutory Auditors. Financial agenda (all dates to be confirmed) 27 May 2026: Annual General Meeting 28 July 2026: H1 2026 results About EUROAPI EUROAPI is focused on reinventing active pharmaceutical ingredients to sustainably meet customers’ and patients’ needs around the world. We are a leading player with approximately 200 products in our portfolio, offering a large span of technologies while also developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. With strong R&D capabilities and five manufacturing sites located in Europe, EUROAPI provides its clients with high-quality API solutions in more than 80 countries. Our 3000+ people are committed to building together the future of public health by advancing and securing access to essential active ingredients, at the core of the healthcare value chain. EUROAPI is listed on Euronext Paris: EAPI. Find out more at and follow us on LinkedIn . Media Relations contact: Laurence Bollack Tel.: +33 (0)6 81 86 80 19 mr@euroapi.com Investor Relations contact: Sophie Palliez-Capian Tel.: +33 (0)6 87 89 33 51 Sophie.palliez@euroapi.com Léa Massonneau Tel: +33 (0)7 60 32 29 50 lea.massonneau@euroapi.com Forward-Looking Statements Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group’s current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 “Risk factors” of the Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 1, 2025. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based. Consolidated Income Statement (in € million) 31-Dec-25 31-Dec-24 Net sales 848.2 911.9 Other revenues 4.4 7.3 Cost of sales (707.7) (776.8) Gross profit 144.8 142.4 Selling and distribution expenses (35.5) (37.6) Research and development expenses (27.3) (25.8) Administrative and general expenses (80.3) (89.4) Other operating income and expense 1.8 2.0 Impairment of assets (77.8) (18.8) Restructuring costs and similar items (60.9) (93.1) Other gains and losses, and litigation 4.4 0.0 Operating income/(loss) (130.6) (120.4) Financial expenses (11.7) (28.1) Financial income 4.2 9.0 Income/(loss) before tax (138.2) (139.6) Income tax expense (72.9) 9.0 Net income/(loss) (211.2) (130.6) Consolidated Balance Sheet (in € million) 31-Dec-25 31-Dec-24 Goodwill 0.0 0.0 Property, plant and equipment 450.9 491.3 Right-of-use assets 35.7 38.0 Intangible assets 26.7 38.1 Other non-current assets 4.4 4.6 Deferred tax assets 18.5 87.2 Non-current assets 536.3 659.2 Inventories 495.2 524.2 Trade receivables 114.9 161.3 Other current assets 44.5 44.6 Cash and cash equivalents 113.8 73.0 Assets held for sale 0.0 27.2 Current assets 768.4 830.3 Total assets 1,304.7 1,489.5 (in € million) 31-Dec-25 31-Dec-24 Equity attributable to owners of the parent 788.0 983.5 Total equity 788.0 983.5 Non-current lease liabilities 16.3 13.2 Provisions 150.6 164.4 Other non-current liabilities 54.7 17.1 Deferred tax liabilities 0.0 (0.0) Non-current liabilities 221.6 194.7 Trade payables 110.5 104.9 Other current liabilities 135.5 135.4 Current lease liabilities 3.6 5.3 Short-term debt and other financial liabilities 45.5 50.6 Liabilities related to assets held for sale 0.0 15.2 Current liabilities 295.1 311.2 Total equity and liabilities 1,304.7 1,489.5 Consolidated Statements of Cash Flow (in € million) 31-Dec-25 31-Dec-24 Net income / (loss) (211.2) (130.6) Depreciation & amortization 140.5 76.8 Gains and losses on disposals of non-current assets, net of tax (4.4) 0.0 Income tax expense 72.9 (9.0) Other profit or loss items with no cash effect and reclass of interest 10.5 25.8 Operating cash flow before changes in working capital 8.4 (36.9) (Increase)/decrease in inventories 38.9 94.0 (Increase)/decrease in trade receivables 45.4 52.2 Increase/(decrease) in trade payables 1.6 (46.8) Net change in other current assets and other current liabilities 34.3 60.4 Net cash provided by operating activities 128.5 122.9 Acquisitions of property, plant and equipment and intangible assets (78.5) (108.0) Proceeds/(payments) arising from the disposal of businesses 1.5 0.0 Net cash (used in) investing activities (77.0) (108.0) Capital increases - - Net issuance of perpetual subordinated notes - 197.3 Repayment of lease liabilities (5.4) (5.5) Net change in short-term debt (5.0) (155.0) Finance costs paid (3.0) (10.9) Acquisitions and disposals of treasury shares 0.0 (0.1) Other net cash flow arising from financing activities 0.2 0.7 Net cash provided by financing activities (13.3) 26.5 Impact of exchange rates on cash and cash equivalents 0.3 (0.6) Net change in cash and cash equivalents 38.6 40.8 Reconciliation of Consolidated Operating Income (EBIT) to restated Core EBITDA (in € million) 31-Dec-25 31-Dec-24 Operating income (130.6) (120.4) Depreciation, amortization, and impairment of assets 140.5 76.8 EBITDA 9.9 (43.6) Restructuring costs and similar items (excluding depreciation and amortization) 58.8 87.1 Allocations net of reversals of unutilized provisions for environmental risks 0.8 4.9 Other (3.3) 2.0 Core EBITDA 66.2 50.4 Core EBITDA 7.8% 5.5% (in € million) 31-Dec-25 Operating income (130.6) Depreciation and amortization 140.5 EBITDA 9.9 Restructuring costs and similar items (excluding depreciation and amortization) 58.8 ow Idle costs 36.1 ow employee-related expenses 13.7 ow internal and external costs related to Transformation 6.6 ow other 2.8 Allocations net of reversals of unutilized provisions for environmental risks 0.8 Other (3.3) Core EBITDA 66.2 1 Selling, Distribution, R&D, Administrative and General Expenses 2 See operational drivers of the outlook page 8 3 On a comparable basis vs 2025 4 Methodology update impacts total scope 1&2 and % share of renewable energy 5 Market based 6 See glossary page 9 7 This includes an adjustment in the allocation of sales between Sanofi and Other Clients following the change in Opella’s majority shareholders. Since 01 May 2025, sales to Opella have been reported under the Other Client Segment (€50m between May and December 2025). 8 See appendix page 14 9 Under-activity triggered by the implementation of FOCUS-27 10 Including accrued interests 11 See detailed in Consolidated Cash Flow Statement page 14 12 Haverhill contributed to €14 million in net sales and €3 million in Core EBITDA in FY 2025 consolidated results, compared to €35 million net sales and €(1) million Core EBITDA in 2024. The capital gain impacting FY 2025 EBITDA was €4.4 million euros. 13 Selling, Distribution, R&D, Administrative and General Expenses 14 Excluding Haverhill (disposed), and Brindisi (planned to be divested), 15 € 10 to 15 million revenues expected from discontinued APIS in 2026 compared to around €70 million in 2025 Attachment EUROAPI_Press release_20260303

2025/26 Interim financial results, Q1 2025/26 1 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth 1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested capital 2 was 15%. • Organic growth rates by business area: Ostomy Care 4%, Continence Care 7%, Voice & Respiratory Care 8%, Wound & Tissue Repair 5%, and Interventional Urology 8% . • Soft start in Ostomy Care, as expected, driven by negative growth in China and a high baseline in the US. The growth momentum is expected to pick up rest of year. • Growth in Continence Care was driven by continued strong contribution from Luja™ for both male and female users. • Voice & Respiratory Care growth was driven by good momentum in Laryngectomy, while Tracheostomy was impacted by order phasing. • Wound & Tissue Repair: - Soft Q1 in Kerecis with 10% organic growth and 1% EBIT margin before PPA amortisation. Performance in Q1 reflects significant sales disruption from Medicare reimbursement changes in the outpatient setting and one-off costs to enhance Kerecis’ go-to-market model under the new Medicare reimbursement model. The significant uncertainty in the skin substitutes market is expected to continue throughout the year. Long-term, Kerecis is expected to see continued strengthening of its competitive position relative to peers, due to its unique technology based on intact fish-skin, backed by strong clinical evidence. - Advanced Wound Dressings declined 3% due to the voluntary product return of all Biatain® Adhesive dressings in China, impacting Q1 negatively with around DKK 25 million. • Strong start in Interventional Urology driven by strong growth in the US Men’s Health business and recovery in Kidney & Bladder Health, following the voluntary product recall initiated in Q1 2024/25. • EBIT 1,3 was DKK 1,850 million. EBIT in constant currencies increased 3% compared to last year, while reported EBIT decreased 3% from last year. The EBIT margin 1,3 was 26%, against 27% last year, negatively impacted by the temporary reduction in Kerecis EBIT margin in the quarter. • Return on invested capital (ROIC) after tax before special items was 15%, on par with last year 4 . • The free cash flow-to-sales ratio was 26%, compared to 24% last year 5 driven by lower net financial items. • Coloplast US has agreed to purchase the outstanding shares of Uromedica, a privately held medical technology company specialising in the treatment of stress urinary incontinence whereby Uromedica will become a wholly owned subsidiary of Coloplast US. The Uromedica Board of Directors has recommended shareholders vote in favor of the transaction. The transaction is expected to close in February 2026, subject to customary closing conditions and requisite Uromedica shareholder approval. FY 2025/26 guidance unchanged: around 7% organic revenue growth and around 7% EBIT growth in constant currencies 6 . Return on invested capital of around 16% 2 . • Organic revenue growth assumes continued good momentum in Chronic Care. • Following a strong Q1, Interventional Urology is now expected to deliver high single-digit growth vs. mid single-digit growth previously. • Kerecis is now expected to deliver growth of around 10% vs. previously around 25%, reflecting the significant sales disruption from Medicare reimbursement changes in the outpatient setting and a higher uncertainty around the timing of recovery. • Reported growth in DKK is now expected at around 4%, with around 3%-points negative impact from currencies and small negative impact from the skin care divestment (two months impact). • EBIT 6 growth in constant currencies assumes stable inflation levels, production ramp up costs and new investments related to the Impact4 strategy. Significant uplift in Kerecis EBIT margin rest of year with Kerecis full year EBIT margin of around double-digit. • Capex-to-sales ratio still expected around 5%. The effective tax rate is still expected around 22%. • ROIC still expected around 16%, up around 1%-point compared to 15% adjusted last year 2,4 . ”We deliver a soft start to the year with 6% organic growth, EBIT growth in constant currencies of 3%, and an EBIT margin of 26% in Q1, reflecting a lower quarter in Kerecis due to significant sales disruption from reimbursement changes in the outpatient setting. Long-term, we continue to believe Kerecis is well-positioned to win in the skin substitutes market based on its unique technology based on intact fish-skin, backed by strong clinical evidence. In Chronic Care, our businesses continue to deliver solid underlying growth across all regions except China, which reported negative growth. I am also pleased to see a solid start to the year in Interventional Urology, driven by strong growth in our US Men’s Health business and recovery in Kidney & Bladder Health,” says Lars Rasmussen, interim CEO of Coloplast. 1. Before special items expenses of DKK -35 million in Q1 2025/26 2. After tax, before special items. 3. Before special items expenses of DKK -74 million in Q1 2024/25. 4. Last year adjusted for the impact from the Kerecis IP transfer. 5. Free cash flow adjustments: FY 2024/25 adjusted for the Skin Care divestment. 6. Before special items expenses of around DKK 50 million in FY 2025/26. Conference call Coloplast will host a conference call on Friday, 6 February 2026 at 11.00 CET. The call is expected to last about one hour. To actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast - Q1 2025/26 conference call For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Kristine Husted Munk Sr. Director, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: dkkhu@coloplast.com Simone Dyrby Helvind Sr. Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 2981 Email: dksdk@coloplast.com Press and media Peter Mønster Head of Media Relations & Corporate Content Tel. +45 4911 2623 Email: dkpete@coloplast.com Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. The Coloplast story begins back in 1954. Elise Sørensen is a nurse. Her sister Thora has just had an ostomy operation and is afraid to go out in public, fearing that her stoma might leak. Listening to her sister’s problems, Elise conceives the idea of the world’s first adhesive ostomy bag. Based on Elise’s idea, Aage Louis-Hansen, a civil engineer and plastics manufacturer, and his wife Johanne Louis Hansen, a trained nurse, created the ostomy bag. A bag that does not leak, giving Thora – and thousands of people like her – the chance to live the life they want. A simple solution that makes a difference. Today, the Coloplast Group develops products and services that help millions of people live more independent lives through solutions tailored to their needs. Globally, our business areas include Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology. The Coloplast logo is a registered trademark of Coloplast A/S. © 2026-02 All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark Attachment 01_2026_Q1_2025-26_Earnings_release